Nasus Pharma Ltd. (AMEX: NSRX) Stock Competitors & Peer Comparison
See NSRX's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NSRX and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NSRX | $3.46 | +2.06% | 29.8M | -4.80 | -$0.72 | N/A |
| RPRX | $56.77 | -0.86% | 25.2B | 10.81 | $5.25 | +1.60% |
| CORT | $110.77 | +2.61% | 12B | 316.49 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $90.22 | +0.89% | 8B | 644.43 | $0.14 | N/A |
| KNSA | $76.06 | -0.59% | 5.8B | 84.51 | $0.90 | N/A |
| TRLV | $8.75 | -2.78% | 1.5B | -20.83 | -$0.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| CUVL | $6.68 | -0.65% | 336.6M | N/A | N/A | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
NSRX vs RPRX Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, RPRX has a market cap of 25.2B. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while RPRX trades at $56.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas RPRX's P/E ratio is 10.81. In terms of profitability, NSRX's ROE is +0.00%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, NSRX is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
NSRX vs CORT Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, CORT has a market cap of 12B. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while CORT trades at $110.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas CORT's P/E ratio is 316.49. In terms of profitability, NSRX's ROE is +0.00%, compared to CORT's ROE of +0.08%. Regarding short-term risk, NSRX is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
NSRX vs WBA Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas WBA's P/E ratio is -1.64. In terms of profitability, NSRX's ROE is +0.00%, compared to WBA's ROE of -0.42%. Regarding short-term risk, NSRX is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
NSRX vs LQDA Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, LQDA has a market cap of 8B. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while LQDA trades at $90.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas LQDA's P/E ratio is 644.43. In terms of profitability, NSRX's ROE is +0.00%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, NSRX is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
NSRX vs KNSA Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, KNSA has a market cap of 5.8B. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while KNSA trades at $76.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas KNSA's P/E ratio is 84.51. In terms of profitability, NSRX's ROE is +0.00%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, NSRX is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check KNSA's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
NSRX vs TRLV Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while TRLV trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas TRLV's P/E ratio is -20.83. In terms of profitability, NSRX's ROE is +0.00%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, NSRX is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check TRLV's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
NSRX vs HROWL Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas HROWL's P/E ratio is N/A. In terms of profitability, NSRX's ROE is +0.00%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, NSRX is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
NSRX vs HROWM Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas HROWM's P/E ratio is N/A. In terms of profitability, NSRX's ROE is +0.00%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, NSRX is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check HROWM's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
NSRX vs CUVL Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, CUVL has a market cap of 336.6M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while CUVL trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas CUVL's P/E ratio is N/A. In terms of profitability, NSRX's ROE is +0.00%, compared to CUVL's ROE of N/A. Regarding short-term risk, NSRX is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check CUVL's competition here
LifeMD, Inc. (NASDAQ: LFMD)
NSRX vs LFMD Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, LFMD has a market cap of 172.2M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while LFMD trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas LFMD's P/E ratio is -7.12. In terms of profitability, NSRX's ROE is +0.00%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, NSRX is more volatile compared to LFMD. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check LFMD's competition here
LifeMD, Inc. (NASDAQ: LFMDP)
NSRX vs LFMDP Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, LFMDP has a market cap of 160M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while LFMDP trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas LFMDP's P/E ratio is -722.96. In terms of profitability, NSRX's ROE is +0.00%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, NSRX is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check LFMDP's competition here
Circle8 Group, Inc. (NASDAQ: CIRC)
NSRX vs CIRC Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, CIRC has a market cap of 65.1M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while CIRC trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas CIRC's P/E ratio is -1.64. In terms of profitability, NSRX's ROE is +0.00%, compared to CIRC's ROE of +0.00%. Regarding short-term risk, NSRX is more volatile compared to CIRC. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check CIRC's competition here
Rite Aid Corporation (NYSE: RAD)
NSRX vs RAD Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas RAD's P/E ratio is -0.05. In terms of profitability, NSRX's ROE is +0.00%, compared to RAD's ROE of +2.76%. Regarding short-term risk, NSRX is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
NSRX vs GLTO Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas GLTO's P/E ratio is -1.78. In terms of profitability, NSRX's ROE is +0.00%, compared to GLTO's ROE of -1.22%. Regarding short-term risk, NSRX is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check GLTO's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
NSRX vs SCYX Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, SCYX has a market cap of 33M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while SCYX trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas SCYX's P/E ratio is -1.53. In terms of profitability, NSRX's ROE is +0.00%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, NSRX is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check SCYX's competition here
Stablecoin Development Corp. (AMEX: SDEV)
NSRX vs SDEV Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, SDEV has a market cap of 28.2M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while SDEV trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas SDEV's P/E ratio is -0.18. In terms of profitability, NSRX's ROE is +0.00%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, NSRX is more volatile compared to SDEV. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check SDEV's competition here
Biofrontera Inc. (NASDAQ: BFRI)
NSRX vs BFRI Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, BFRI has a market cap of 16.3M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while BFRI trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas BFRI's P/E ratio is -1.19. In terms of profitability, NSRX's ROE is +0.00%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, NSRX is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
NSRX vs CJJD Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas CJJD's P/E ratio is -0.46. In terms of profitability, NSRX's ROE is +0.00%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, NSRX is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
NSRX vs SSY Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas SSY's P/E ratio is -2.86. In terms of profitability, NSRX's ROE is +0.00%, compared to SSY's ROE of -0.09%. Regarding short-term risk, NSRX is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
NSRX vs POM Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, POM has a market cap of 5.9M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while POM trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas POM's P/E ratio is -0.17. In terms of profitability, NSRX's ROE is +0.00%, compared to POM's ROE of +0.16%. Regarding short-term risk, NSRX is more volatile compared to POM. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check POM's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
NSRX vs PAVS Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, PAVS has a market cap of 5.3M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while PAVS trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas PAVS's P/E ratio is -0.07. In terms of profitability, NSRX's ROE is +0.00%, compared to PAVS's ROE of -0.27%. Regarding short-term risk, NSRX is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check PAVS's competition here
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD)
NSRX vs HKPD Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, HKPD has a market cap of 4.6M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while HKPD trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas HKPD's P/E ratio is -7.01. In terms of profitability, NSRX's ROE is +0.00%, compared to HKPD's ROE of -0.14%. Regarding short-term risk, NSRX is more volatile compared to HKPD. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check HKPD's competition here
AIxCrypto Holdings, Inc. (NASDAQ: AIXC)
NSRX vs AIXC Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, AIXC has a market cap of 4.3M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while AIXC trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas AIXC's P/E ratio is -0.09. In terms of profitability, NSRX's ROE is +0.00%, compared to AIXC's ROE of -0.94%. Regarding short-term risk, NSRX is less volatile compared to AIXC. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check AIXC's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
NSRX vs MDVL Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas MDVL's P/E ratio is -0.05. In terms of profitability, NSRX's ROE is +0.00%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, NSRX is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
NSRX vs ATNFW Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas ATNFW's P/E ratio is N/A. In terms of profitability, NSRX's ROE is +0.00%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, NSRX is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
NSRX vs BGMSP Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, NSRX's ROE is +0.00%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, NSRX is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check BGMSP's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
NSRX vs BGMS Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while BGMS trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas BGMS's P/E ratio is -0.26. In terms of profitability, NSRX's ROE is +0.00%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, NSRX is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check BGMS's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
NSRX vs AZNH Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas AZNH's P/E ratio is 38.35. In terms of profitability, NSRX's ROE is +0.00%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, NSRX is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
NSRX vs LFLYW Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, NSRX's ROE is +0.00%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, NSRX is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check LFLYW's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
NSRX vs SBFMW Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, SBFMW has a market cap of 175.2K. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while SBFMW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas SBFMW's P/E ratio is N/A. In terms of profitability, NSRX's ROE is +0.00%, compared to SBFMW's ROE of -0.26%. Regarding short-term risk, NSRX is less volatile compared to SBFMW. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check SBFMW's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
NSRX vs ESRX Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas ESRX's P/E ratio is 10.69. In terms of profitability, NSRX's ROE is +0.00%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, NSRX is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check ESRX's competition here
POZEN Inc. (NASDAQ: POZN)
NSRX vs POZN Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, POZN has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas POZN's P/E ratio is N/A. In terms of profitability, NSRX's ROE is +0.00%, compared to POZN's ROE of +0.61%. Regarding short-term risk, NSRX is more volatile compared to POZN. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check POZN's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
NSRX vs OREX Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, OREX has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas OREX's P/E ratio is -0.14. In terms of profitability, NSRX's ROE is +0.00%, compared to OREX's ROE of -0.54%. Regarding short-term risk, NSRX is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check OREX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
NSRX vs IPXL Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas IPXL's P/E ratio is -10.11. In terms of profitability, NSRX's ROE is +0.00%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, NSRX is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check IPXL's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
NSRX vs CPD Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, CPD has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas CPD's P/E ratio is N/A. In terms of profitability, NSRX's ROE is +0.00%, compared to CPD's ROE of N/A. Regarding short-term risk, NSRX is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check CPD's competition here
Shire plc (NASDAQ: SHPG)
NSRX vs SHPG Comparison August 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 29.8M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.46 on the AMEX, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.80, whereas SHPG's P/E ratio is 11.35. In terms of profitability, NSRX's ROE is +0.00%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, NSRX is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check SHPG's competition here